Replies to post #40478 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

Will an EPIC-like trial with low doses + a statin/Aspirin be restarted?

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94040906

Dr. Harvey Berger's goal is still to bring Iclusig to the front line. He said:

"It really depends on the dose and the data we collect in the front line. Clearly, we need to run trials at lower doses. We don't rule out the front line. But it would have to be based upon data, not just hypothesis."

And the data collected in the front line to be present at the 55th ASH is promising:

"Ponatinib is effective as initial therapy for CML-CP resulting in high rates of cytogenetic and molecular responses at early timepoints. Therapy with ponatinib is well tolerated with transient elevated lipase being the most common toxicity. In view of the frequency of dose reductions and considering the excellent responses achieved, the trial has been modified to explore 30 mg as initial dose."
https://ash.confex.com/ash/2013/webprogram/Paper64338.html

Transient elevated lipase rather than blood clot is the most common toxicity.

With such great data, why shouldn't Ponatinib go to the front line and the ultimate line (1st line and last line) to help the CML patients live a good life?

Ariad may partner Iclusig. The big pharm companies know the huge $ potential of Iclusig. The CML patients need the life-saving drug.

[grandma_of_jbraika]

"We don't rule out the front line. But it would have to be based upon data, not just hypothesis. It really depends on the dose and the data we collect in the front line. Clearly, we need to run trials at lower doses," said Ariad CEO Harvey Berger.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94671488